AU2013339823A1 - A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (HCC) - Google Patents

Abstract

3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof for the use for the treatment of hepatocellular carcinoma (HCC).

Description

WO 2014/067610 PCT/EP2013/002998 A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (HCC) 5 FIELD OF THE INVENTION This invention relates to 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin 2-yll-benzyl}-6-oxo- 1,6-d ihyd ro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof for the use for the 10 treatment of hepatocellular carcinoma (HCC). BACKGROUND OF THE INVENTION The invention had the object of finding novel pharmaceutical compositions having 15 valuable properties, in particular those which can be used for the preparation of medicaments. Moreover, aim of this invention are new compositions for the prevention and 20 treatment of hepatocellular carcinoma. It has been found that 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2 yl]-benzyl}-6-oxo-1,6-d ihyd ro-pyridazin-3-yl)-benzonitrile according to the 25 invention or a pharmaceutically acceptable salt and/or solvate thereof has very valuable pharmacological properties while being well tolerated. HCC is the 5th most common malignancy worldwide, with 667,000 new cases worldwide and 17,500 in USA. 80% of patients present with advanced or 30 unresectable disease at diagnosis. In Western countries, approx. 40% of patients are eligible for a potential curative treatment (resection, transplantation, local ablation) whereas approx. 20% are eligible for chemoembolization. In well-selected patients resection and transplantation 35 provide 5-year survival rates of 70%, 50% of patients relapse within 3 years. Here we demonstrate that 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)- WO 2014/067610 PCT/EP2013/002998 -2 pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof is active in HCC tumors with signs of active c-Met signaling. 5 Before the approval of sorafenib there was no effective systemic treatment increasing survival in HCC: conventional cytotoxic agents given as monotherapy or in combination regimen had low response rates and did not lead to survival advantage (Thomas MB, O'Beirne JP, Furuse J, Chan AT, 10 Abou-Alfa G, Johnson P; Ann Surg Oncol. 2008 Apr;15(4):1008-14). However, although PFS times have been improved by sorafenib, PFS and overall survival remain limited. Secondary resistance occurs after several weeks of drug exposure. After progression there is currently no other 15 therapeutic option. Due to the high unmet medical need in HCC alternative effective treatment options are needed. PRIOR ART 20 3-(1 -{3-[5-(1 -Methyl-piperidin-4-ylmethoxy)-pyrimid in-2-yl]-benzyl}-6-oxo- 1,6 dihydro-pyridazin-3-yl)-benzonitrile has been described in WO 2009/006959 Al. 3-(1 -{3-[5-(1 -Methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6 25 dihydro-pyridazin-3-yl)-benzonitrile hydrochloride hydrate has been described in WO 2009/007074 Al. SUMMARY OF THE INVENTION 30 The invention relates to 3-(1 -{3-[5-(1 -methyl-piperid in-4-ylmethoxy)-pyrimid in 2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof for the use for the 35 treatment of hepatocellular carcinoma

(HCC).

WO 2014/067610 PCT/EP2013/002998 -3 Moreover, the invention relates to 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy) pyrimidin-2-yl]-benzyl}- 6 -oxo-l,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride hydrate for the use for the treatment of hepatocellular carcinoma (HCC). 5 Moreover, the invention relates to 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy) pyrimidin-2-yl]-benzyl}- 6 -oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof, wherein the compound is administered to a patient in an amount of 100 mg to 800 mg per 10 day. Moreover, the invention relates to 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy) pyrimidin-2-yl)-benzyl}- 6 -oxo-l,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof, wherein the 15 compound is administered orally. Moreover, the invention relates to the use of 3-(1-{3-[5-(1-methyl-piperidin-4 ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo- 1,6-d ihyd ro-pyridazin-3-yl) benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof for the manufacture of a medicament for the treatment of hepatocellular carcinoma 20 (HCC). Moreover, the invention relates to the use of 3-(1-{3-[5-(1-methyl-piperidin-4 ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl) benzonitrile hydrochloride hydrate for the manufacture of a medicament for the 25 treatment of hepatocellular carcinoma (HCC). Moreover, the invention relates to the use as described above, wherein 3-(1 -{3-[5-(1 -methyl-piperid in-4-ylmethoxy)-pyrimidin-2-yl]-benzy}-6 oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable 30 salt and/or solvate thereof or 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6 dihydro-pyridazin-3-yl)-benzonitrile hydrochloride hydrate, wherein the compound is administered to a patient in an amount of 100 mg to 800 mg per day, preferably in an amount of 200 mg to 700 mg per week, 35 particularly preferably in an amount of 250 mg to 350 mg per day. Moreover, the invention relates to the use as described above, WO 2014/067610 PCT/EP2013/002998 -4 wherein 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6 oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof or 3-(1 -{3-[5-(1 -methyl-piperid in-4-ylmethoxy)-pyrimid in-2-yl]-benzyl}-6-oxo-1,6 5 dihydro-pyridazin-3-yl)-benzonitrile hydrochloride hydrate wherein the compound is administered orally. The therapy with 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl] 10 benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof or 3-(1 -{3-[5-(1 -methyl-piperid in-4-ylmethoxy)-pyrimid in-2-yl]-benzyl}-6-oxo-1,6 dihydro-pyridazin-3-yl)-benzonitrile hydrochloride hydrate may include 15 optionally further treatment with radiation. The invention relates furthermore to a new therapy form comprising the start of the administration of 3-(1-{3-[5-(1 methyl-piperid in-4-ylmethoxy)-pyrimid in-2-yl]-benzyl}-6-oxo-1,6-dihyd ro pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof prior to radiotherapy for the treatment of hepatocellular carcinoma 20 (HCC). The invention also relates to the optically active forms (stereoisomers), the enantiomers, the racemates, the diastereomers and the hydrates and solvates 25 of the compound. The invention also relates to the solvates of the salts of the compound e.g. the mono- or dihydrate of the hydrochloride. 30 The term solvates of the compound is taken to mean adductions of inert solvent molecules onto the compounds which form owing to their mutual attractive force. Solvates are, for example, mono- or dihydrates or alcoholates. The expression "effective amount" denotes the amount of a medicament or of 35 a pharmaceutical active ingredient which causes in a tissue, system, animal or WO 2014/067610 PCT/EP2013/002998 human a biological or medical response which is sought or desired, for example, by a researcher or physician. In addition, the expression "therapeutically effective amount" denotes an amount which, compared with a corresponding subject who has not received 5 this amount, has the following consequence: improved treatment, healing, prevention or elimination of a disease, syndrome, condition, complaint, disorder or side-effects or also the reduction in the advance of a disease, complaint or disorder. 10 The expression "therapeutically effective amount" also encompasses the amounts which are effective for increasing normal physiological function. Pharmaceutical salts and other forms 15 The said compounds according to the invention can be used in their final non salt form. On the other hand, the present invention also encompasses the use of these compounds in the form of their pharmaceutically acceptable salts, which can be derived from various organic and inorganic acids and bases by procedures known in the art. Pharmaceutically acceptable salt forms of 3-(1 20 {3-[5-(1 -methyl-piperid in-4-ylmethoxy)-pyrimid in-2-yl]-benzyl}-6-oxo-1,6 dihydro-pyridazin-3-yl)-benzonitrile and N-((S)-2,3-dihydroxy-propyl)-3-(2 fluoro-4-iodo-phenylamino)-isonicotinamide are for the most part prepared by conventional methods. 25 If a compound contains a carboxyl group, one of its suitable salts can be formed by reacting the compound with a suitable base to give the corresponding base-addition salt. Such bases are, for example, alkali metal hydroxides, including potassium hydroxide, sodium hydroxide and lithium 30 hydroxide; alkaline earth metal hydroxides, such as barium hydroxide and calcium hydroxide; alkali metal alkoxides, for example potassium ethoxide and sodium propoxide; and various organic bases, such as piperidine, diethanolamine and N-methylglutamine. The aluminium salts of the compounds are likewise included. In the case of certain compounds acid-addi 35 tion salts can be formed by treating these compounds with pharmaceutically acceptable organic and inorganic acids, for example hydrogen halides, such as WO 2014/067610 PCT/EP2013/002998 -6 hydrogen chloride, hydrogen bromide or hydrogen iodide, other mineral acids and corresponding salts thereof, such as sulfate, nitrate or phosphate and the like, and alkyl- and monoarylsulfonates, such as ethanesulfonate, toluenesulfonate and benzenesulfonate, and other organic acids and 5 corresponding salts thereof, such as acetate, trifluoroacetate, tartrate, maleate, succinate, citrate, benzoate, salicylate, ascorbate and the like. Accordingly, pharmaceutically acceptable acid-addition salts of the compounds include the following: acetate, adipate, alginate, arginate, aspartate, benzoate, benzene 10 sulfonate (besylate), bisulfate, bisulfite, bromide, butyrate, camphorate, camphorsulfonate, caprylate, chloride, chlorobenzoate, citrate, cyclopentane propionate, digluconate, dihydrogenphosphate, dinitrobenzoate, dodecyl sulfate, ethanesulfonate, fumarate, galacterate (from mucic acid), galacturo 15 nate, glucoheptanoate, gluconate, glutamate, glycerophosphate, hemi succinate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isethionate, iso butyrate, lactate, lactobionate, malate, maleate, malonate, mandelate, metaphosphate, methanesulfonate, methylbenzoate, monohydrogenphos 20 phate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, oleate, palmoate, pectinate, persulfate, phenylacetate, 3-phenylpropionate, phosphate, phosphonate, phthalate, but this does not represent a restriction. 25 Furthermore, the base salts of the compounds according to the invention include aluminium, ammonium, calcium, copper, iron(Ill), iron(II), lithium, magnesium, manganese(ll), manganese(lI), potassium, sodium and zinc salts, but this is not intended to represent a restriction. Of the above-men 30 tioned salts, preference is given to ammonium; the alkali metal salts sodium and potassium, and the alkaline earth metal salts calcium and magnesium. Salts of the compounds which are derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary and tertiary amines, substituted amines, also including naturally occurring substituted 35 amines, cyclic amines, and basic ion exchanger resins, for example arginine, betaine, caffeine, chloroprocaine, choline, N,N'-dibenzylethylenediamine WO 2014/067610 PCT/EP2013/002998 -7 (benzathine), dicyclohexylamine, diethanolamine, diethylamine, 2-diethyl aminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lidocaine, lysine, meglumine, N-methyl-D 5 glucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethanolamine, triethylamine, trimethylamine, tripropyl amine and tris(hydroxymethyl)methylamine (tromethamine), but this is not intended to represent a restriction. 10 Compounds of the present invention which contain basic nitrogen-containing groups can be quaternised using agents such as (C-C 4 )alkyl halides, for example methyl, ethyl, isopropyl and tert-butyl chloride, bromide and iodide; 15 di(C-C4)alkyl sulfates, for example dimethyl, diethyl and diamyl sulfate; (C1o

C

18 )alkyl halides, for example decyl, dodecyl, lauryl, myristyl and stearyl chloride, bromide and iodide; and aryl(C-C4)alkyl halides, for example benzyl chloride and phenethyl bromide. Both water- and oil-soluble compounds according to the invention can be prepared using such salts. 20 The above-mentioned pharmaceutical salts which are preferred include acetate, trifluoroacetate, besylate, citrate, fumarate, gluconate, hemisuccinate, hippurate, hydrochloride, hydrobromide, isethionate, mandelate, meglumine, 25 nitrate, oleate, phosphonate, pivalate, sodium phosphate, stearate, sulfate, sulfosalicylate, tartrate, thiomalate, tosylate and tromethamine, but this is not intended to represent a restriction. 30 Particular preference is given to hydrochloride, dihydrochloride, hydrobromide, maleate, mesylate, phosphate, sulfate and succinate. The acid-addition salts of basic compounds are prepared by bringing the free base form into contact with a sufficient amount of the desired acid, causing the 35 formation of the salt in a conventional manner. The free base can be regenerated by bringing the salt form into contact with a base and isolating the WO 2014/067610 PCT/EP2013/002998 -8 free base in a conventional manner. The free base forms differ in a certain respect from the corresponding salt forms thereof with respect to certain physical properties, such as solubility in polar solvents; for the purposes of the invention, however, the salts otherwise correspond to the respective free base 5 forms thereof. As mentioned, the pharmaceutically acceptable base-addition salts of the compounds are formed with metals or amines, such as alkali metals and 10 alkaline earth metals or organic amines. Preferred metals are sodium, potassium, magnesium and calcium. Preferred organic amines are N,N' dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methyl-D-glucamine and procaine. 15 The base-addition salts of acidic compounds according to the invention are prepared by bringing the free acid form into contact with a sufficient amount of the desired base, causing the formation of the salt in a conventional manner. The free acid can be regenerated by bringing the salt form into contact with an 20 acid and isolating the free acid in a conventional manner. The free acid forms differ in a certain respect from the corresponding salt forms thereof with respect to certain physical properties, such as solubility in polar solvents; for the purposes of the invention, however, the salts otherwise correspond to the 25 respective free acid forms thereof. With regard to that stated above, it can be seen that the expression "phar maceutically acceptable salt" in the present connection is taken to mean an 30 active ingredient which comprises a compound in the form of one of its salts, in particular if this salt form imparts improved pharmacokinetic properties on the active ingredient compared with the free form of the active ingredient or any other salt form of the active ingredient used earlier. The pharmaceutically acceptable salt form of the active ingredient can also provide this active 35 ingredient for the first time with a desired pharmacokinetic property which it did not have earlier and can even have a positive influence on the WO 2014/067610 PCT/EP2013/002998 -9 pharmacodynamics of this active ingredient with respect to its therapeutic efficacy in the body. The invention furthermore relates to medicaments comprising at least one 5 compound and/or pharmaceutically acceptable salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants. 10 Pharmaceutical formulations can be administered in the form of dosage units which comprise a predetermined amount of active ingredient per dosage unit. Such a unit can comprise, for example, 0.5 mg to 1 g, preferably 1 mg to 700 mg, particularly preferably 5 mg to 100 mg, of a compound according to 15 the invention, depending on the condition treated, the method of administration and the age, weight and condition of the patient, or pharmaceutical formulations can be administered in the form of dosage units which comprise a predetermined amount of active ingredient per dosage unit. Preferred dosage unit formulations are those which comprise a daily dose or part-dose, as 20 indicated above, or a corresponding fraction thereof of an active ingredient. Furthermore, pharmaceutical formulations of this type can be prepared using a process which is generally known in the pharmaceutical art. 25 Pharmaceutical formulations can be adapted for administration via any desired suitable method, for example by oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) 30 methods. Such formulations can be prepared using all processes known in the pharmaceutical art by, for example, combining the active ingredient with the excipient(s) or adjuvant(s). Pharmaceutical formulations adapted for oral administration can be adminis 35 tered as separate units, such as, for example, capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible WO 2014/067610 PCT/EP2013/002998 - 10 foams or foam foods; or oil-in-water liquid emulsions or water-in-oil liquid emulsions. Thus, for example, in the case of oral administration in the form of a tablet or 5 capsule, the active-ingredient component can be combined with an oral, non toxic and pharmaceutically acceptable inert excipient, such as, for example, ethanol, glycerol, water and the like. Powders are prepared by comminuting the compound to a suitable fine size and mixing it with a pharmaceutical 10 excipient comminuted in a similar manner, such as, for example, an edible carbohydrate, such as, for example, starch or mannitol. A flavour, preservative, dispersant and dye may likewise be present. 15 Capsules are produced by preparing a powder mixture as described above and filling shaped gelatine shells therewith. Glidants and lubricants, such as, for example, highly disperse silicic acid, talc, magnesium stearate, calcium stearate or polyethylene glycol in solid form, can be added to the powder mixture before the filling operation. A disintegrant or solubiliser, such as, for 20 example, agar-agar, calcium carbonate or sodium carbonate, may likewise be added in order to improve the availability of the medicament after the capsule has been taken. 25 In addition, if desired or necessary, suitable binders, lubricants and disin tegrants as well as dyes can likewise be incorporated into the mixture. Suitable binders include starch, gelatine, natural sugars, such as, for example, glucose or beta-lactose, sweeteners made from maize, natural and synthetic rubber, 30 such as, for example, acacia, tragacanth or sodium alginate, carboxymethyl cellulose, polyethylene glycol, waxes, and the like. The lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. The disintegrants include, without being restricted thereto, starch, methylcellulose, 35 agar, bentonite, xanthan gum and the like. The tablets are formulated by, for example, preparing a powder mixture, granulating or dry-pressing the mixture, WO 2014/067610 PCT/EP2013/002998 - 11 adding a lubricant and a disintegrant and pressing the entire mixture to give tablets. A powder mixture is prepared by mixing the compound comminuted in a suitable manner with a diluent or a base, as described above, and optionally with a binder, such as, for example, carboxymethylcellulose, an alginate, 5 gelatine or polyvinylpyrrolidone, a dissolution retardant, such as, for example, paraffin, an absorption accelerator, such as, for example, a quaternary salt, and/or an absorbant, such as, for example, bentonite, kaolin or dicalcium phosphate. The powder mixture can be granulated by wetting it with a binder, 10 such as, for example, syrup, starch paste, acadia mucilage or solutions of cellulose or polymer materials and pressing it through a sieve. As an alternative to granulation, the powder mixture can be run through a tabletting machine, giving lumps of non-uniform shape, which are broken up to form 15 granules. The granules can be lubricated by addition of stearic acid, a stearate salt, talc or mineral oil in order to prevent sticking to the tablet casting moulds. The lubricated mixture is then pressed to give tablets. The compounds according to the invention can also be combined with a free-flowing inert excipient and then pressed directly to give tablets without carrying out the 20 granulation or dry-pressing steps. A transparent or opaque protective layer consisting of a shellac sealing layer, a layer of sugar or polymer material and a gloss layer of wax may be present. Dyes can be added to these coatings in order to be able to differentiate between different dosage units. 25 Oral liquids, such as, for example, solution, syrups and elixirs, can be prepared in the form of dosage units so that a given quantity comprises a pre-specified amount of the compound. Syrups can be prepared by dissolving the compound 30 in an aqueous solution with a suitable flavour, while elixirs are prepared using a non-toxic alcoholic vehicle. Suspensions can be formulated by dispersion of the compound in a non-toxic vehicle. Solubilisers and emulsifiers, such as, for example, ethoxylated isostearyl alcohols and polyoxyethylene sorbitol ethers, preservatives, flavour additives, such as, for example, peppermint oil or natural 35 sweeteners or saccharin, or other artificial sweeteners and the like, can likewise be added.

WO 2014/067610 PCT/EP2013/002998 -12 The dosage unit formulations for oral administration can, if desired, be en capsulated in microcapsules. The formulation can also be prepared in such a way that the release is extended or retarded, such as, for example, by coating 5 or embedding of particulate material in polymers, wax and the like. The compounds and salts, solvates, tautomers and stereoisomers thereof can also be administered in the form of liposome delivery systems, such as, for 10 example, small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from various phospholipids, such as, for example, cholesterol, stearylamine or phosphatidylcholines. 15 The compounds and the salts, solvates, tautomers and stereoisomers thereof can also be delivered using monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds can also be coupled to soluble polymers as targeted medicament carriers. Such polymers may encompass polyvinylpyrrolidone, pyran copolymer, polyhydroxypropyl 20 methacrylamidophenol, polyhydroxyethylaspartamidophenol or polyethylene oxide polylysine, substituted by palmitoyl radicals. The compounds may furthermore be coupled to a class of biodegradable polymers which are suitable for achieving controlled release of a medicament, for example 25 polylactic acid, poly-epsilon-caprolactone, polyhydroxybutyric acid, poly orthoesters, polyacetals, polydihydroxypyrans, polycyanoacrylates and crosslinked or amphipathic block copolymers of hydrogels. 30 Pharmaceutical formulations adapted for transdermal administration can be administered as independent plasters for extended, close contact with the epidermis of the recipient. Thus, for example, the active ingredient can be delivered from the plaster by iontophoresis, as described in general terms in Pharmaceutical Research, 3(6), 318 (1986). 35 WO 2014/067610 PCT/EP2013/002998 - 13 Pharmaceutical compounds adapted for topical administration can be for mulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils. 5 Pharmaceutical formulations adapted for rectal administration can be ad ministered in the form of suppositories or enemas. Pharmaceutical formulations adapted for nasal administration in which the 10 carrier substance is a solid comprise a coarse powder having a particle size, for example, in the range 20-500 microns, which is administered in the manner in which snuff is taken, i.e. by rapid inhalation via the nasal passages from a container containing the powder held close to the nose. Suitable formulations 15 for administration as nasal spray or nose drops with a liquid as carrier substance encompass active-ingredient solutions in water or oil. Pharmaceutical formulations adapted for administration by inhalation encom pass finely particulate dusts or mists, which can be generated by various types 20 of pressurised dispensers with aerosols, nebulisers or insufflators. Pharmaceutical formulations adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions comprising antioxidants, 25 buffers, bacteriostatics and solutes, by means of which the formulation is rendered isotonic with the blood of the recipient to be treated; and aqueous and non-aqueous sterile suspensions, which may comprise suspension media and thickeners. The formulations can be administered in single-dose or 30 multidose containers, for example sealed ampoules and vials, and stored in freeze-dried (lyophilised) state, so that only the addition of the sterile carrier liquid, for example water for injection purposes, immediately before use is necessary. Injection solutions and suspensions prepared in accordance with the recipe can be prepared from sterile powders, granules and tablets. 35 WO 2014/067610 PCT/EP2013/002998 - 14 It goes without saying that, in addition to the above particularly mentioned constituents, the formulations may also comprise other agents usual in the art with respect to the particular type of formulation; thus, for example, for mulations which are suitable for oral administration may comprise flavours. 5 A therapeutically effective amount of a compound depends on a number of factors, including, for example, the age and weight of the animal, the precise condition that requires treatment, and its severity, the nature of the formulation 10 and the method of administration, and is ultimately determined by the treating doctor or vet. However, an effective amount of a compound according to the invention is generally in the range from 0.1 to 100 mg/kg of body weight of the recipient (mammal) per day and particularly typically in the range from 1 to 15 10 mg/kg of body weight per day. Thus, the actual amount per day for an adult mammal weighing 70 kg is usually between 70 and 700 mg, where this amount can be administered as a single dose per day or usually in a series of part doses (such as, for example, two, three, four, five or six) per day, so that the total daily dose is the same. An effective amount of a salt, solvate, tautomer 20 and stereoisomer thereof can be determined as the fraction of the effective amount of the compound according to the invention per se. It can be assumed that similar doses are suitable for the treatment of other conditions mentioned above. 25 The anti-cancer treatment defined herein may be applied as a sole therapy or may involve, in addition to the composition of the invention, conventional surgery or radiotherapy. 30 "Treating" as used herein, means an alleviation, in whole or in part, of symptoms associated with a disorder or disease, or slowing, or halting of further progression or worsening of those symptoms, or prevention or 35 prophylaxis of the disease or disorder in a subject at risk for developing the disease or disorder.

WO 2014/067610 PCT/EP2013/002998 - 15 The term "effective amount" in connection with a compound can mean an amount capable of alleviating, in whole or in part, symptoms associated with a disorder or disease, or slowing or halting further progression or worsening of those symptoms, or preventing or providing prophylaxis for the disease or 5 disorder in a subject having or at risk for developing a disease disclosed herein, such as cancer, The term "therapeutically effective" or "therapeutically effective amount" refers to an amount of a drug effective to treat a disease or disorder in a mammal. In 10 the case of cancer, the therapeutically effective amount of the drug may reduce the number of cancer cells; reduce the tumor size; inhibit (i.e., slow to some extent and preferably stop) cancer cell infiltration into peripheral organs; inhibit (i.e., slow to some extent and preferably stop) tumor metastasis; inhibit, 15 to some extent, tumor growth; and/or relieve to some extent one or more of the symptoms associated with the cancer. To the extent the drug may prevent growth and/or kill existing cancer cells, it may be cytostatic and/or cytotoxic. For cancer therapy, efficacy can, for example, be measured by assessing the 20 time to disease progression (TTP) and/or determining the response rate (RR). USE 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6 25 dihydro-pyridazin-3-yl)-benzonitrile hydrochloride hydrate is suitable as pharmaceutical active ingredient for mammals, especially for humans, in the treatment of hepatocellular carcinoma. 30 Experimental Evaluation of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl] benzyl}-6-oxo-1, 6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride hydrate in the HCC xenograft model MHCC97H 35 WO 2014/067610 PCT/EP2013/002998 - 16 Summary: 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6 oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride hydrate displays a greater activity than sorafenib in a hepatocarcinoma xenograft model and in HCC primary explants, all of which are characterized by high c-Met and/or 5 HGF expression. While sorafenib led to substantial body weight loss in most HCC explant models (8/9) at all doses tested (50 mg/kg/5 out of 7 days and 60 mg/kg/qd), 3-(1 -{3-[5-(1 -methyl-piperid in-4-ylmethoxy)-pyrimidin-2-yl]-benzy} 6-oxo-1,6-d ihyd ro-pyridazin-3-yl)-benzonitrile hydrochloride hydrate was well 10 tolerated in all mice as indicated by the lack of substantial weight loss of animals. Data from pre-clinical in-house studies highlight the role of c-Met in maintenance and progression of HCC and indicate that c-Met inhibition might 15 be an attractive treatment option for HCC. The MHCC97H cell line has been established from subcutaneous xenograft of a metastatic model of human HCC in nude mice (LCI-D20) and has a tendency to metastasize to the lungs (Wu FS, Zheng SS, Wu U, Teng LS, Ma ZM, Zhao WH, Wu W; Liver Int. 2007 20 Jun; 27(5):700-7). MHCC97H cells co-express c-Met and HGF and also secrete alpha feto protein (AFP), a fetal-specific glycoprotein antigen that is used as a tumor marker in the management of patients with HCC. 25 Treatment of established fast growing subcutaneous MHCC97H tumors with 3 (1 -{3-[5-(1 -methyl-piperid in-4-ylmethoxy)-pyrimid in-2-yl]-benzyl}-6-oxo-1,6 dihydro-pyridazin-3-yl)-benzonitrile hydrochloride hydrate completely inhibited growth and induced regressions. In comparison to 3-(1-{3-[5-(1-methyl 30 piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl) benzonitrile hydrochloride hydrate treatment of subcutaneous MHCC97H xenografts, administration of sorafenib resulted only in marginal anti tumor activity with no tumor regressions. To evaluate the effect of c-Met inhibition under more physiological conditions, MHCC97H cells were engrafted 35 orthotopically in the liver of mice.

WO 2014/067610 PCT/EP2013/002998 - 17 Oral administration of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2 yI]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride hydrate starting one week after tumor fragment implantation exhibited significant anti tumor activity, resulting in complete regression in all mice at the end of 5 treatment at day 35. As a surrogate endpoint, body weight was followed throughout the study. Body weight loss in the vehicle group could be observed from day 18 onward, probably caused by increased tumor burden in the liver and/or lung metastasis. In contrast, for mice treated with the c-Met inhibitor, no 10 body weight loss could be detected. At the end of the treatment period AFP levels in the circulation were analyzed. Whereas in the control group high AFP levels were detectable, no AFP was measurable in the mice treated with 3-(1 {3-[5-(1 -methyl-piperid in-4-ylmethoxy)-pyrimid in-2-yl]-benzyl}-6-oxo-1,6 15 dihydro-pyridazin-3-yl)-benzonitrile hydrochloride hydrate. Subcutaneous MHCC97H tumor model - comparison 3-(1-{3-[5-(1-methyl piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-l,6-dihydro-pyridazin-3-yl) benzonitrile hydrochloride hydrate and sorafenib monotherapy: 20 Method: Male BalB/c nude mice (6-8 week old) where subcutaneously injected with human MHCC97H liver tumor cells and were divided into treatment groups (ten animals in one group) after the tumors were established (ca. 500mm 3 ). Respective groups were administered orally with the 3-(1-{3-[5-(1 25 methyl-piperidin-4-ylmethoxy)-pyrimid in-2-yl]-benzyl}-6-oxo-1,6-d ihyd ro pyridazin-3-yl)-benzonitrile hydrochloride hydrate at different doses (10, 30 and 100 mg/kg) for 5 days on and 2 days on or daily with sorafenib (50mg/kg). At the end of treatment T/C values were calculated and tumor regrowth was 30 observed. Results: All doses of 3-(1 -{3-[5-(1 -methyl-piperidin-4-ylmethoxy)-pyrimidin-2 yl]-benzyl}-6-oxo- 1,6-d ihyd ro-pyridazi n-3-yl)-benzonitrile hydrochloride hydrate showed significant anti-tumor activity inducing tumor regression with T/C ratios 35 of -57%, -93% and -93%, respectively and a tumor growth delay (TGD, time to reach a tumor volume of 1000mm 3 ) of 24, 53 and more as 53 days, WO 2014/067610 PCT/EP2013/002998 - 18 respectively. Treatment of sorafenib showed less anti-tumor activity compared to MSC2156119J with a T/C value of 27%. Orthotopic MHCC97H tumor model - 3-(1-{3-[5-(1-methyl-piperidin-4 5 ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl) benzonitrile hydrochloride hydrate monotherapy: Method: In male BaIB/c nude mice (7-8 week old) MHCC97H tumor fragments (2-3 mm 3 ) where orthotopically implanted into the left lobe of the liver. After 1 10 week of intrahepatic implantation animals were divided into treatment groups (ten animals in one group). Respective groups were administered orally with 3 (1 -{3-[5-(1 -methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6 dihydro-pyridazin-3-yl)-benzonitrile hydrochloride hydrate at 100 mg/kg/5 days 15 on and 2 days off for 5 weeks. At the end of treatment, tumor size and tumor weight were measured, plasma AFP levels and lung metastases analyzed. Results: Treatment with 3-(1 -{3-[5-(1 -methyl-piperid in-4-ylmethoxy)-pyrimid in 2-yl]-benzyl}-6-oxo- 1,6-d ihyd ro-pyridazin-3-yl)-benzon itrile hydrochloride 20 hydrate induced significant anti-tumor activity resulting in primary tumor regression (p<0.001) and reduction lung metastases (p<0.01). AFP levels in plasma of mice analyzed at the end of treatment were also significantly reduced (p<0.001). Treatment of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy) 25 pyrimidin-2-yli]-benzyl}- 6 -oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride hydrate was well tolerated. Evaluation of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl] 30 benzyl}-6-oxo- 1, 6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride hydrate in primary HCC explants: Summary: To study the therapeutic potential of 3-(1-{3-[5-(1-methyl-piperidin 4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl) 35 benzonitrile hydrochloride hydrate in HCC patients, the activity of 3-(1-{3-[5-(l methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro- WO 2014/067610 PCT/EP2013/002998 -19 pyridazin-3-yl)-benzonitrile hydrochloride hydrate was evaluated in a preclinical phase i type trial (PP2T trial) with human primary HCC explants. Treatment of nine subcutaneous, established primary explants resulted in 1/9 complete responses (CR), 2/9 stable diseases (SD) and marginal activity in one 5 additional model. The activity of 3-(1 -{3-[5-(1 -methyl-piperidin-4-ylmethoxy) pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride hydrate correlated positive with the activation status of the c Met receptor expressed in these models, as indicated by c-Met and HGF 10 expression levels. None of the models with no or only low signs of detectable c-Met signaling (c-Met, phospho c-Met and/HGF levels) responded to 3-(1-{3 [5-(1 -methyl-piperid in-4-ylmethoxy)-pyrimid in-2-yl]-benzyl}-6-oxo-1,6-dihyd ro pyridazin-3-yl)-benzonitrile hydrochloride hydrate in monotherapy and no 15 enhanced activity in combination with sorafenib has been observed. Method: Male BaIB/c nude mice (6-8 week old) where subcutaneously transplanted with a primary HCC tumor fragment. Animals were divided into treatment groups (12 animals in one group) after the tumors were established. 20 Respective groups were administered orally with the 3-(1-{3-[5-(1-methyl piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-l,6-dihydro-pyridazin-3-yl) benzonitrile hydrochloride hydrate at 100mg/kg for 5 out of 7 days. At the end of treatment T/C values were calculated and tumor regrowth was observed. Results: 3-(1 -{3-[5-(1 -methyl-piperid in-4-ylmethoxy)-pyrimidin-2-ylI]-benzyl}-6 25 oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride hydrate (100 mg/kg/5 out of 7 days) significantly inhibited the growth of 4 out of the 9 models (LIM612, LIM801, LIM1098, LIM941; T/C values of 49% to -97%). Sorafenib (50 mg/kg/5 out of 7 days) displayed an anti-tumor activity in 7 out of 9 models 30 (LIM348, LIM612, LIM941, LIM752, LIM1098, LIM801, LIM1081 with T/C values of 45% to -8%). 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2 yl]-benzyl}-6-oxo-l,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride hydrate exhibited better anti-tumor activity than sorafenib monotherapy in LIM801 and 35 LIM612, two models with strong signs of c-Met signaling. The combination of sorafenib with 3-(1-{3-[5-(1-methyl-piperid i n-4-ylmethoxy)-pyrimid in-2-yl]- WO 2014/067610 PCT/EP2013/002998 - 20 benzyl}-6-oxo- 1,6-d ihyd ro-pyridazi n-3-yl)-be nzo nitrile hydrochloride hydrate enhanced anti-tumor activity of best monotherapy in 2 out of 9 models (LIM1098 and LIM752 with T/C values of -32% and 4%, respectively). 5 Determination of c-Met phospho c-Met and HGF protein levels in primary explants: Method: c-Met, phospho c-Met, and HGFalpha expression was studied with 10 IHC in satellite animals of human primary tumor explants and xenografts (Table 1). The xenografts were excised, sectioned into few pieces, fixed in 4% buffered formaldehyde solution during 48 hrs at RT and embedded in paraffin. Sections of 3pm of formaldehyde fixed paraffin embedded (FFPE) tissue were 15 mounted on positively charged SuperFrost@Plus slides (Menzel-Gliser, Braunschweig, Germany). The immunohistochemical staining procedure starting with the deparaffinization of sections was done with the staining instrument Discovery TM or the Discovery@ XT (Ventana Medical Systems, Inc., Tucson, USA). After deparaffinization sections were heated for epitope 20 retrieval in Tris-EDTA buffer pH 8. Endogenous peroxidase was blocked by incubation in 3% hydrogen peroxide (part of OmniMap T M Kit, Ventana Medical Systems). Sections were incubated with in PBS diluted antibodies. and then with the secondary antibody, the HRP conjugated polymers of the OmniMap 25 Kit, for 16 min at 37'C. Horseradish peroxidase (HRP) catalyzes the 3,3' diaminobenzidine tetrahydorchloride (DAB)/H202 reaction to produce an insoluble dark brown precipitate that can be visualized. Sections were counterstained with hematoxylin. Slides were washed in tap water, dehydrated, 30 and mounted with glass coverslips in permanent mounting media Entellan@ Neu (VWR, Germany). The detailed run protocols, generated by the staining instruments, are stored at Merck Serono, Darmstadt, Germany. Immunohistochemical stainings were scanned with the help of the MiraxSCAN (Zeiss) with a resolution x/y: 1 pixel = 0.23 x 0.23 pm2. The scannings were analyzed with the image analysis software Visiopharm Integrator System (VIS; WO 2014/067610 PCT/EP2013/002998 -21 V 4.0.3.0; Visiopharm A/S, Denmark). Viable tissue area was outlined avoiding obvious necrotic areas and connective tissue. For the determination of the amount of antigen present, positive brown stained area was calculated as percent area of the viable tissue area. Antibody staining (arbitrary units) is 5 calculated as Antibody staining (AU) = Positive area (%) * (255-Intensity)/100 of the brown colour. Results: In explants of human hepatocellular carcinoma (HCC), high c-Met, phospho-Met and moderate HGFalpha expression could be detected in single 10 explants with the help of immunohistochemistry (IHC). Out of 9 HCC explants, 8 were positive for c-Met. Two of the explants (LIM1098 and LIM612) showed high pTyr 1234/1235 Met and pTyr 1349 Met expression. Additional 3 explant tumors showed low to moderate pTyr1349-Met expression. Due to high 15 background staining with the detection system for the HGF antibody clone B-3 (mouse IgG) in several explant xenografts, the tumors could not be analyzed with the help of image analysis. A semiquantitative scoring was performed (C. Wilm) by comparing the specific anti-HGF staining with the mouse IgG isotype 20 control staining. Scores are: 0 = negative 1 = low 25 2 = medium 3 = high Two out of 9 HCC explants exhibited low to moderate HGF alpha expression. 30 LIM612 with low HGF expression was highly positive for phospho-Met. LIM801 with moderate HGF expression was negative for phospho-Met. 35

Claims (8)

1. 3-(1 -{3-[5-(1 -methyl-piperid in-4-ylmethoxy)-pyrimidin-2-ylj]-benzyl}-6-oxo 1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable 5 salt and/or solvate thereof for the use for the treatment of hepatocellular carcinoma (HCC).

2. 3-(1 -{3-[5-(1 -methyl-piperid in-4-ylmethoxy)-pyrimid in-2-yl]-benzyl}-6-oxo 10 1,6-dihydro-pyridazin-3-yI)-benzonitrile hydrochloride hydrate for the use for the treatment of hepatocellular carcinoma (HCC).

3. 3-(1 -{3-[5-(1 -methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzy}-6-oxo 15 1,6-dihydro-pyridazin-3-yl)-benzonitrile according to claim 1 or 2, wherein the compound is administered to a patient in an amount of 100 mg to 800 mg per day.

4. 3-(1 -{3-[5-(1 -methyl-piperidin-4-ymethoxy)-pyrimidin-2-y]-benzyl}-6-oxo 20 1,6-dihydro-pyridazin-3-yl)-benzonitrile according to claim 1, 2 or 3, wherein the compound is administered orally.

5. Use of 3-(1 -{3-[5-(1 -methyl-piperid in-4-ylmethoxy)-pyrimid in-2-yl]-benzyl} 25 6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof for the manufacture of a medicament for the treatment of hepatocellular carcinoma (HCC). 30 6. Use of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}

6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride hydrate for the manufacture of a medicament for the treatment of hepatocellular carcinoma (HCC). 35 WO 2014/067610 PCT/EP2013/002998 - 23

7. Use according to claim 5 or 6, wherein the compound is administered to a patient in an amount of 100 mg to 800 mg per day.

8. Use according to claim 5, 6 or 7, wherein the compound is administered 5 orally. 10 15 20 25 30 35